News
Andexxa (coagulation factor Xa [recombinant], inactivated-zhzo) was previously launched under an Early Supply Program with Generation 1 product.
Sprycel plus chemotherapy demonstrated a three-year event-free survival benefit during clinical trials.
The FDA approved trastuzumab-pkrb (Herzuma, Celltrion) as a biosimilar to Herceptin for the treatment of HER2-overexpressing breast cancer.
.jpg "Research Highlights Long-Term Efficacy of PCSK9 Inhibitor")
Evolocumab is approved as an adjunct to diet and other LDL cholesterol-lowering therapies in patients with primary hyperlipidemia and homozygous familial hypercholesterolemia.
Overall response rate and survival in patients with relapsed AML treated with azacitidine plus nivolumab and ipilimumab may be superior to azacitidine plus nivolumab.
About the Specialty Pharmacy Times Industry Guide
The Specialty Pharmacy Times Industry Guide includes comprehensive editorial content relative to all specialty pharmacy stakeholders. Content includes information relative to market trends, commercialization, distribution, order to cash, HUB Services, managed care strategies and DIR fees.
The guide also includes profiles, and a complete list of stakeholders along the patient journey: specialty pharmacies, wholesaler distributors, manufacturers, support services, group purchasing, and trade associations.
